Karimah Sabar Biography and Net Worth



Ms. Es Sabar joined the Company’s Board in July 2021 and is currently the Chairman of the Company’s Nominating and Corporate Governance Committee. She is a corporate director and strategic advisor for private and not for profit organizations. From 2016-2025 she has been the CEO and General Partner at Quark Venture LP, a venture capital investment firm, leading their global health sciences enterprise. Prior to Quark Venture, Ms. Es Sabar was President and CEO at the Centre for Drug Research and Development (CDRD), Canada’s national drug development and commercialization center, responsible for developing and executing on the overall strategic direction. Ms. Es Sabar has held senior management positions with multinational pharmaceutical companies, most notably as Director International Division, and later Global Head Marketing and Business Development at Sanofi Pasteur based in Toronto. She holds degrees in Neurochemistry from the Institute of Psychiatry, University of London, in Biochemistry and Chemistry from the University of Salford Manchester, and an Executive Certificate in Management and Leadership from the MIT Sloan School of Management. Ms. Es Sabar is also the Chair of the Health Biosciences Economic Strategy Table (Government of Canada) and she serves on the board of directors of several biosciences companies. She is a Member of the Order of British Columbia, and recipient of Canada’s Most Powerful Women: Top 100 Award and Canada’s Gold Award for Business Excellence amongst others.

What is Karimah Es Sabar's net worth?

The estimated net worth of Karimah Es Sabar is at least $236.42 thousand as of April 2nd, 2026. Ms. Sabar owns 7,529 shares of Capricor Therapeutics stock worth more than $236,418 as of April 8th. This net worth estimate does not reflect any other assets that Ms. Sabar may own. Learn More about Karimah Es Sabar's net worth.

How do I contact Karimah Es Sabar?

The corporate mailing address for Ms. Sabar and other Capricor Therapeutics executives is 8840 WILSHIRE BLVD 2ND FLOOR, BEVERLY HILLS CA, 90211. Capricor Therapeutics can also be reached via phone at 310-358-3200 and via email at [email protected]. Learn More on Karimah Es Sabar's contact information.

Has Karimah Es Sabar been buying or selling shares of Capricor Therapeutics?

Within the last three months, Karimah Es Sabar has sold $1,908,325.05 of Capricor Therapeutics stock. Most recently, Karimah Es Sabar sold 7,529 shares of the business's stock in a transaction on Thursday, April 2nd. The shares were sold at an average price of $32.00, for a transaction totalling $240,928.00. Following the completion of the sale, the director now directly owns 7,529 shares of the company's stock, valued at $240,928. Learn More on Karimah Es Sabar's trading history.

Who are Capricor Therapeutics' active insiders?

Capricor Therapeutics' insider roster includes Paul Auwaerter (Director), Anthony Bergmann (CFO), David Musket (Director), and Karimah Sabar (Director). Learn More on Capricor Therapeutics' active insiders.

Are insiders buying or selling shares of Capricor Therapeutics?

During the last twelve months, insiders at the biotechnology company sold shares 4 times. They sold a total of 147,529 shares worth more than $4,509,940.10. The most recent insider tranaction occured on April, 2nd when Director Karimah Es Sabar sold 7,529 shares worth more than $240,928.00. Insiders at Capricor Therapeutics own 10.5% of the company. Learn More about insider trades at Capricor Therapeutics.

Information on this page was last updated on 4/2/2026.

Karimah Es Sabar Insider Trading History at Capricor Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/2/2026Sell7,529$32.00$240,928.007,529View SEC Filing Icon  
4/1/2026Sell53,735$31.03$1,667,397.05View SEC Filing Icon  
3/31/2026Sell61,265$30.17$1,848,365.05View SEC Filing Icon  
See Full Table

Karimah Es Sabar Buying and Selling Activity at Capricor Therapeutics

This chart shows Karimah Es Sabar's buying and selling at Capricor Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Capricor Therapeutics Company Overview

Capricor Therapeutics logo
Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders.
Read More

Today's Range

Now: $31.60
Low: $31.29
High: $33.00

50 Day Range

MA: $27.71
Low: $21.57
High: $33.57

2 Week Range

Now: $31.60
Low: $4.30
High: $40.37

Volume

639,962 shs

Average Volume

1,358,890 shs

Market Capitalization

$1.82 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.48